Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin.

Onose G, Mureşanu DF, Ciurea AV, Daia Chendreanu C, Mihaescu AS, Mardare DC, Andone I, Spânu A, Popescu C, Dumitrescu A, Popescu M, Grigorean V and 7 more

Show all authors

Ungur B, Marinescu F, Colibbeanu I, Onose L, Haras M, Sandu A, Spircu T

Journal of medicine and life1 Oct 2009Cited by 28 (Europe PMC)

PMID20108748PMCIDPMC3019019PepBankPUB-20108748

Download PDF PubMedAsk about this study

Jump to 3 results

Summary

BackgroundDiscovery of neurotrophic factors--emblematic: the nerve growth factor (NGF)--resulted in better approaching central nervous system (CNS) lesions. Recently, another crucial property has been unveiled: their rather unique pleiotropic effect. Cerebrolysin is a peptide mixture that penetrates the blood-brain barrier in significant amounts and mimics the effects of NGF.MethodsComparative analysis: Cerebrolysin treated (10 ml x 2/day, i.v. x 3 weeks) vs. non-treated, in patients (all received aside, a rather equivalent complementary, pharmacological and physical, therapy). Two lots of patients, admitted in our Physical & Rehabilitation (neural-muscular) Medical-PR(n-m)M-Clinic Division, during 2007-2009: 69 treated with Cerebrolysin (22 F, 47 M; Average: 59.333; Mean of age: 61.0 Years old; Standard deviation 16.583) and 70 controls (41 F, 29 M; A: 70.014; M.o.a.: 70.5 Y.o.; S.d.: 6.270) were studied. The total number of assessed items was 13: most contributive in relation with the score of Functional Independence Measure at discharge (d FIM), were: admission (a FIM), number of physical therapy days (PT), number of hospitalization days (H), age (A) and--relatively--days until the first knee functional extension (KE). Concomitantly, the main/key, focused on neuro-motor rehabilitative outcomes, functional/analytical parameters, have been assessed regarding the speed in achieving their functional recovery.ResultsConcerning d FIM, there have not been objectified significant differences between the two lots (p=0.2453) but regarding key, focused on neuro-motor rehabilitative outcomes, functional/analytical parameters: KE (p=0.0007) and days until the first time recovery of the ability to walk between parallel bars (WPB--p=0.0000)--highly significant differences in favor of Cerebrolysin lot resulted.ConclusionCerebrolysin administration, as neurorehabilitative outcomes, proved to hasten, statistically significant, especially the recovery of some critical, for standing and walking, parameters. Thus encouraged, we have now initiated a comprehensive national, 5 year retrospective, multi-centre--based on unitary data acquisition frame and mathematical apparatus--study, to evaluate the results of the treatment with Cerebrolysin in traumatic brain injuries (TBI).

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In rehabilitation patients, discharge Functional Independence Measure did not differ significantly between Cerebrolysin and untreated groups.
In plain wordsIn rehabilitation patients, Cerebrolysin treatment was linked to discharge independence scores that did not differ significantly from untreated patients.
Peptide
Cerebrolysin
Outcome
No significant changeFunctional Independence Measure at discharge
Study
n = 139
Comparator
Patients not treated with Cerebrolysin
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
10 ml x 2/day · i.v. · 3 weeksAs given in this study (human).
Measurements
p
0.2453
discharge FIM
Source sentences
Summary
Concerning d FIM, there have not been objectified significant differences between the two lots (p=0.2453)
1 context sentence(design, population, supporting numbers)
Summary · context
Comparative analysis: Cerebrolysin treated (10 ml x 2/day, i.v. x 3 weeks) vs. non-treated, in patients (all received aside, a rather equivalent complementary, pharmacological and physical, therapy).
Show in the study text Report a problemFND-2010874801
02HumanObservational studyEfficacy outcome
In rehabilitation patients, Cerebrolysin shortened time to first knee functional extension compared with untreated patients.
In plain wordsIn rehabilitation patients, Cerebrolysin treatment was linked to faster knee functional extension than in untreated patients.
Peptide
Cerebrolysin
Outcome
DecreaseTime to first knee functional extension
Study
n = 139
Comparator
Patients not treated with Cerebrolysin
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
10 ml x 2/day · i.v. · 3 weeksAs given in this study (human).
Measurements
p
0.0007
knee functional extension
Source sentences
Summary
but regarding key, focused on neuro-motor rehabilitative outcomes, functional/analytical parameters: KE (p=0.0007) and days until the first time recovery of the ability to walk between parallel bars (WPB--p=0.0000)--highly significant differences in favor of Cerebrolysin lot resulted.
1 context sentence(design, population, supporting numbers)
Summary · context
Comparative analysis: Cerebrolysin treated (10 ml x 2/day, i.v. x 3 weeks) vs. non-treated, in patients (all received aside, a rather equivalent complementary, pharmacological and physical, therapy).
Show in the study text Report a problemFND-2010874802
03HumanObservational studyEfficacy outcome
In rehabilitation patients, Cerebrolysin shortened time to recovery of walking between parallel bars compared with untreated patients.
In plain wordsIn rehabilitation patients, Cerebrolysin treatment was linked to faster recovery of walking between parallel bars than in untreated patients.
Peptide
Cerebrolysin
Outcome
DecreaseTime to walking between parallel bars
Study
n = 139
Comparator
Patients not treated with Cerebrolysin
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
10 ml x 2/day · i.v. · 3 weeksAs given in this study (human).
Measurements
p
0
walking between parallel bars
Source sentences
Summary
but regarding key, focused on neuro-motor rehabilitative outcomes, functional/analytical parameters: KE (p=0.0007) and days until the first time recovery of the ability to walk between parallel bars (WPB--p=0.0000)--highly significant differences in favor of Cerebrolysin lot resulted.
1 context sentence(design, population, supporting numbers)
Summary · context
Comparative analysis: Cerebrolysin treated (10 ml x 2/day, i.v. x 3 weeks) vs. non-treated, in patients (all received aside, a rather equivalent complementary, pharmacological and physical, therapy).
Show in the study text Report a problemFND-2010874803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.